In- silico Design of Novel Inhibitors for 5-HT2A Receptor to Recuperate Schizophrenia

Authors

  • Richa Chaudhary Department of Biotechnology, Institute of Engineering & Technology, Uttar Pradesh Technical University, Lucknow, India
  • B N Mishra Department of Biotechnology, Institute of Engineering & Technology, Uttar Pradesh Technical University, Lucknow, India
  • Vivek Srivastava Department of Biotechnology, Institute of Engineering & Technology, Uttar Pradesh Technical University, Lucknow, India
  • Isha Chandra Department of Biotechnology, Institute of Engineering & Technology, Uttar Pradesh Technical University, Lucknow, India

DOI:

https://doi.org/10.37591/(rrjobi).v2i2.382

Abstract

Schizophrenia is a mental disorder characterized by positive symptoms such as disorganized speech, delusions and hallucinations and negative symptoms such as deficits of attention, affective flattening and social withdrawal in nature. There are several receptor involve in schizophrenia, one of these 5-HT2A receptor i.e. serotonin receptor.  The serotonin receptor 5-HT2A has been involved in several neurological conditions and potent 5-HT2A inhibitors have therapeutic effects that use for the treatment of schizophrenia and depression. First and second generations of antipsychotics tend to block receptors in the brain's dopamine pathways, but antipsychotic drugs encompass a wide range of receptor targets. In this study, 3D QSAR analysis using kNN-MFA method was performed on a series of benzathaizapine and pyrrolobenzezapine derivatives as 5-HT2A inhibiters and 5 potent novel 5-HT2A inhibitors discovered. Here, inhibition constants, Ki for 21 antipsychotics, which already approved for clinical treatment, the best model were evaluated using random selection method that use for the division dataset in to training and test set. kNN-MFA methodology with simulating annealing were used for the model building. The selected best QSAR model has training set of 17 molecules and test set of 4 molecules. Significant values of the cross-validated correlation q2 (0.77) and the fitted correlation r2 (0.95) revealed that this model have reasonable power to predict the biological affinity of new compound in interactions serotonin 5-HT2A receptor. The drug likeness of these molecules was checked through ADME property prediction.

 

 Keywords: Serotonin, 5-HT2A receptor, Schizophrenia

Cite this Article

Chaudhary Richa, Mishra B N,  Srivastava Vivek  et  al. In- silico Design of Novel Inhibitors for 5-HT2A Receptor to Recuperate Schizophrenia.  Research & Reviews: A Journal of Bioinformatics. 2015; 2(2): 11–17p

Downloads

Published

2019-03-18

Issue

Vol. 2 No. 2 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.